Ovarian Cancer

Assignment to a dose-dense regimen of paclitaxel given weekly did not prolong progression-free survival compared with paclitaxel given every 3 weeks in a group of patients with ovarian cancer treated with or without bevacizumab.

This review focuses on the clinicopathologic and molecular features of epithelial ovarian cancer, with specific attention to genetic predisposition, morphologic challenges, immunohistochemistry, and molecular features.

The movement of ovarian carcinoma histotypes from ill-defined and poorly reproducible clusters of cases to distinct disease entities clearly has beneficial implications for patient management.

A mouse study found that resveratrol has a significant antitumor effect in an ovarian cancer model, and also suppressed tumor regrowth following cisplatin.

Women older than 70 received less treatment for ovarian cancer than did their younger counterparts, according to the results of a single-center French study.

Women with chemotherapy-naive advanced ovarian cancer gained significant delays in the progression of their disease when adding nintedanib to carboplatin/paclitaxel.

A study in Great Britain found that women diagnosed with female factor infertility were at an increased risk for ovarian cancer.

Muscle attenuation assessed with preoperative CT was an independent prognostic marker in patients with epithelial ovarian cancer.

A new study at a single center in Japan found no significant differences in the rate of BRCA mutations between ovarian cancer patients with or without family histories of the mutations and recommends that BRCA1/2 testing be required for all ovarian cancer patients

A recent study that gave hormone therapy to ovarian cancer patients with severe menopausal symptoms revealed that the treatment had a beneficial survival effect.

Here we discuss the advantages and pitfalls of HIPEC in advanced ovarian cancer, as well as current data and ongoing prospective trials.

The evidence suggests that few centers offer IP therapy routinely. Why? The answer may be that oncologists simply don’t know what to do. There have been three completely distinct regimens, none of which has been used in the outpatient setting.

Based on the currently available scientific evidence, HIPEC should not be considered a standard therapeutic option after optimal cytoreduction in advanced ovarian cancer, nor should it be offered outside of a clinical trial.

A small study showed that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer.

Beta-blockers were associated with increased overall survival in women with epithelial ovarian cancer, according to a retrospective study.

Testing women for non-BRCA gene mutations that can confer breast or ovarian cancer risk has clinical management consequences for both the women and their family members.

Women younger than 35 with low-grade serous carcinoma of the ovary or peritoneum or those who still had persistent disease at the completion of primary therapy were found to have worse disease outcomes.

A study has found that mutations in the genes RAD51C and RAD51D confer risk for epithelial ovarian cancer, causing approximately one in every 90 high-grade and one in every 120 epithelial ovarian cancer occurrences.

Despite trials showing a benefit when combining IP and IV chemo for ovarian cancer, fewer than 50% of eligible patients are currently receiving this treatment.

The FDA has granted Orphan Drug Designation to the immunotherapy DPX-Survivac, which is in development for the treatment of ovarian cancer.

Ovarian cancer progression may be driven by the activation of an endoplasmic reticulum stress response factor that disrupts the function of dendritic cells and, subsequently, antitumor fighting T cells.

Women with ovarian cancer with ADAMTS mutations were significantly more sensitive to chemotherapy and had longer platinum-free durations.

A phase III trial found that primary chemotherapy resulted in similar survival compared with primary surgery in newly diagnosed advanced ovarian cancer patients.

Preoperative albumin level and number of extended cytoreductive procedures in ovarian cancer patients predicted the likelihood of surgical complications.

The purpose of this paper is to provide a review of site-specific treatment options that involve the targeting of angiogenesis in gynecologic malignancies.

Use of an ovarian cancer risk algorithm that incorporated serum CA-125 screening was able to double the number of invasive epithelial ovarian cancers detected.

Survival for women with ovarian cancer has improved since 1975, according to the results of a recent study.

Combination treatment with the PARP inhibitor olaparib plus the PI3K inhibitor BKM120 showed a benefit in subsets of breast cancer and ovarian cancer patients.

Researchers have used observational study data to better define risks for breast and ovarian cancers associated with mutations in the BRCA1 or BRCA2 genes.

The use of intraperitoneal chemotherapy for the treatment of advanced ovarian cancer resulted in a survival benefit over intravenous chemotherapy.